Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR97276A in uncomplicated and severe malaria
NCT00739206Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Aug 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of albitiazolium bromide in malaria, sponsored by Sanofi. Started Aug 2008; status: terminated.
02
Drugs
albitiazolium bromide
03
Conditions
malaria
Beyond the preview
Go deeper on NCT00739206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00739206.